TIDMSNG
RNS Number : 4363Q
Synairgen plc
19 June 2020
Press Release
Synairgen plc
('Synairgen' or the 'Company')
Grant of options
Southampton, UK - 19 June 2020: Synairgen plc (LSE: SNG), the
respiratory drug discovery and development company, announces that
on 18 June 2020 the Board of Synairgen granted options ('Options')
over 1,767,985 ordinary shares of one pence each in the capital of
the Company ('Ordinary Shares') at an exercise price of one pence
per Ordinary Share. The Options represent in aggregate 1.18 per
cent. of the Company's issued share capital.
The Options are issued under the Company's existing Long Term
Incentive Plan and are exercisable between 18 June 2023 and 17 June
2030, subject to achievement of performance criteria related to the
increase in the total shareholder return of the Company. Following
this grant, Synairgen has 10,255,500 options in issue, representing
6.86 per cent. of the Company's issued share capital.
Included in the number of Options granted on 18 June 2020, the
following Options were issued to directors:
Director Options Issued
Richard Marsden 490,817
---------------
Dr. Phillip
Monk 354,483
---------------
John Ward 381,749
---------------
Following the issue of the Options, the interests of the
directors of the Company at
18 June 2020 are as follows:
Percentage
holding of
Ordinary fully diluted
Director Total options shares Total interest share capital
Richard Marsden 3,533,839 367,825 3,901,664 2.44%
-------------- ---------- --------------- ---------------
Dr. Phillip Monk 1,948,582 244,600 2,193,182 1.37%
-------------- ---------- --------------- ---------------
John Ward 2,481,064 367,577 2,848,641 1.78%
-------------- ---------- --------------- ---------------
Simon Shaw - 1,531,239 1,531,239 0.96%
-------------- ---------- --------------- ---------------
Iain Buchanan 212,765 112,741 325,506 0.20%
-------------- ---------- --------------- ---------------
Dr. Bruce Campbell - 322,830 322,830 0.20%
-------------- ---------- --------------- ---------------
Prof. Stephen Holgate - 886,931 886,931 0.56%
-------------- ---------- --------------- ---------------
Jody Brookes and Victoria Tear, also persons disclosing
managerial responsibilities, were granted 135,576 and 101,270
Options respectively.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No. 596/2014 ('MAR')
For further information, please contact:
Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Finance Director
Tel: + 44 (0) 23 8051 2800
finnCap
Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate
Finance)
Alice Lane, Manasa Patil (ECM)
Tel: + 44 (0) 20 7220 0500
Consilium Strategic Communications (Financial Media and
Investor
Relations)
Mary-Jane Elliott, Sue Stuart, Olivia Manser
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5700
Notes for Editors
About Synairgen
Synairgen is a respiratory drug discovery and development
company founded by University of Southampton Professors Stephen
Holgate, Donna Davies and Ratko Djukanovic. The business, focused
primarily on lung viral defence in asthma and COPD, uses its
differentiating human biology BioBank platform and world-renowned
international academic KOL network to discover and develop novel
therapies for respiratory disease.
Synairgen is quoted on AIM (LSE: SNG). For more information
about Synairgen, please see www.synairgen.com
1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated
with them ('PCA')
a) Name Richard Marsden
2. Reason for notification
a) Position / status Chief Executive Officer
b) Initial notification / amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Synairgen plc
b) LEI 213800IMMTOPPDF8HD24
4. Details of the transaction(s):
a) Description of the financial instrument Options over ordinary shares of 1p each
Identification code
GB00B0381Z20
b) Nature of the transaction Award of Options under the Synairgen LTIP
c) Price(s) and volume(s) 490,817 Options awarded
d) Aggregated information n/a
Aggregated volume Price
e) Date of the transaction 18 June 2020
f) Place of the transaction Outside a trading venue
1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated
with them ('PCA')
a) Name Dr Phillip Monk
2. Reason for notification
a) Position / status Chief Scientific Officer
b) Initial notification / amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Synairgen plc
b) LEI 213800IMMTOPPDF8HD24
4. Details of the transaction(s):
a) Description of the financial instrument Options over ordinary shares of 1p each
Identification code
GB00B0381Z20
b) Nature of the transaction Award of Options under the Synairgen LTIP
c) Price(s) and volume(s) 354,483 Options awarded
d) Aggregated information n/a
Aggregated volume Price
e) Date of the transaction 18 June 2020
f) Place of the transaction Outside a trading venue
1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated
with them ('PCA')
a) Name John Ward
2. Reason for notification
a) Position / status Finance Director
b) Initial notification / amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Synairgen plc
b) LEI 213800IMMTOPPDF8HD24
4. Details of the transaction(s):
a) Description of the financial instrument Options over ordinary shares of 1p each
Identification code
GB00B0381Z20
b) Nature of the transaction Award of Options under the Synairgen LTIP
c) Price(s) and volume(s) 381,749 Options awarded
d) Aggregated information n/a
Aggregated volume Price
e) Date of the transaction 18 June 2020
f) Place of the transaction Outside a trading venue
1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated
with them ('PCA')
a) Name Jody Brookes
2. Reason for notification
a) Position / status Head of Clinical Operations
b) Initial notification / amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Synairgen plc
b) LEI 213800IMMTOPPDF8HD24
4. Details of the transaction(s):
a) Description of the financial instrument Options over ordinary shares of 1p each
Identification code
GB00B0381Z20
b) Nature of the transaction Award of Options under the Synairgen LTIP
c) Price(s) and volume(s) 135,576 Options awarded
d) Aggregated information n/a
Aggregated volume Price
e) Date of the transaction 18 June 2020
f) Place of the transaction Outside a trading venue
1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated
with them ('PCA')
a) Name Victoria Tear
2. Reason for notification
a) Position / status Head of Laboratories
b) Initial notification / amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Synairgen plc
b) LEI 213800IMMTOPPDF8HD24
4. Details of the transaction(s):
a) Description of the financial instrument Options over ordinary shares of 1p each
Identification code
GB00B0381Z20
b) Nature of the transaction Award of Options under the Synairgen LTIP
c) Price(s) and volume(s) 101,270 Options awarded
d) Aggregated information n/a
Aggregated volume Price
e) Date of the transaction 18 June 2020
f) Place of the transaction Outside a trading venue
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCEAPKPFSXEEFA
(END) Dow Jones Newswires
June 19, 2020 02:00 ET (06:00 GMT)
Grafico Azioni Synairgen (LSE:SNG)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Synairgen (LSE:SNG)
Storico
Da Apr 2023 a Apr 2024
